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Abstract
Down syndrome (DS), as a phenotypic result of trisomy 21, is the most frequent aneuploidy at birth and the most common known genetic
cause of mental retardation. DS is also characterized by other phenotypes affecting many organs, including brain, muscle, heart, limbs,
gastrointestinal tract, skeleton, and blood. Any of the human chromosome 21 (Hsa21) genes may contribute to some of the DS phenotypes.
To determine which of the Hsa21 genes are involved in DS, the effects of disrupting and overexpressing individual human gene orthologs in
model organisms, such as the nematode Caenorhabditis elegans, can be analyzed. Here, we isolated and characterized C21orf80 (human
chromosome 21 open reading frame 80), a potential novel protein O-fucosyltransferase gene that encodes three alternatively spliced
transcripts. Transient expression of tagged C21orf80 proteins suggests a primary intracellular localization in the Golgi apparatus. To gain
insight into the biological role of C21orf80 and its potential role in DS, we isolated its C. elegans ortholog, pad-2, and performed RNA
interference (RNAi) and overexpression experiments. pad-2(RNAi) embryos showed failure to undergo normal morphogenesis. Transgenic
worms with elevated dosage of pad-2 displayed severe body malformations and abnormal neuronal development. These results show that
pad-2 is required for normal development and suggest potential roles for C21orf80 in the pathogenesis of DS.
D 2004 Elsevier Inc. All rights reserved.
Down syndrome (DS), caused by trisomy 21, is the most
common genetic cause of mental retardation, with an
incidence of approximately 1 in 700 live births. DS patients
show several clinical manifestations that affect multiple
organs with variable penetrance. In addition to mental
retardation and facial characteristics, there are numerous
other phenotypes associated with DS, including heart dis-
ease and early onset Alzheimer disease [3]. The completion
of the genomic sequence of human chromosome 21 (Hsa21)
[12] and its mouse syntenic regions [23,31] is facilitating the
discovery of the Hsa21 genes [2,7,26,27]. After the charac-
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terization of the Hsa21 gene repertoire, the next issue is to
uncover their functions and to determine which ones are
involved in the phenotypes of DS [9,28]. Model organisms
will be essential to determine the function of these genes by
studying the functional/phenotypical effects of their inacti-
vation and overexpression. The nematode Caenorhabditis
elegans is an attractive experimental model organism to
study gene function. Despite its apparent rudimentary orga-
nization, the main cell types affected in DS, including
muscle cells and neurons, can be individually identified
[1,30]. Importantly, approximately 25% of Hsa21 genes
exhibit a high level of sequence homology to genes within
the C. elegans genome [8].
Here, we report the isolation and initial characterization
of C21orf80, a potential new protein O-fucosyltransferase
that maps to Hsa21. Protein O-fucosyltransferase is an
emerging class of enzymes that add O-fucose to conserved
serine or threonine residues in the epidermal growth factor-
like domains of a number of cell surface and secreted
proteins. Recent studies have shown that signaling events
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involved in development can be regulated by O-fucosylation
[11]. To determine the biological role of C21orf80 in
development and its potential involvement in DS, its C.
elegans ortholog pad-2 was isolated and characterized. Both
disruption and overexpression of pad-2 revealed essential
functions in normal development and suggested possible
roles for C21orf80 in the pathogenesis of DS.
Results
Isolation of the human C21orf80 gene and its C. elegans
ortholog
In silico analysis of approximately 1 Mb of 21q22.3
genomic sequence revealed the existence of a new gene,
subsequently named C21orf80. The C21orf80 gene is com-
posed of 10 exons and spans over 24 kb of genomic sequence
between ADARB1 and COL18A1. We identified three differ-
ent alternatively spliced transcripts. C21orf80a (AJ302080)
is a 424-amino-acid putative protein. This isoform results
from introns 8 and 9 not being spliced. C21orf80b
(AJ302079) contains all the exons, is 3055 bp in size, and
encodes a putative 380-amino-acid protein. C21orf80c
(AY066015) results from the splicing out of exon 9, is
2849 bp in size, and encodes a putative 429-amino-acid
protein (Fig. 1A). Homology searches against publicly avail-
able databases revealed that C21orf80 is also known as
POFUT2 (FUT13; AJ575591), a member of a newly identi-
fied protein O-fucosyltransferase family, POFUT2 [20].
The human C21orf80b protein sequence was used to
search the mouse, Drosophila, and C. elegans genome data-
bases. A unique C. elegans ortholog of C21orf80 (Z36282,
ORF K10G9.3) was identified and confirmed by RT-PCR. It
is composed of five exons, spans approximately 2 kb of
genomic sequence, and encodes a putative protein of 426
amino acids that shows 45% identity to the human C21orf80b
protein (Fig. 1B). No alternative transcripts were identified in
C. elegans. The C. elegans ortholog of C21orf80 was named
pad-2, which stands for C. elegans patterning defective-2
(see later in the text [10]). The mouse C21orf80 ortholog
(AF455270) encodes a protein of 429 amino acids and shows
92% identity with the human C21orf80b protein. The Dro-
sophila ortholog O-fucosyltransferase 2 (AAF45629) enco-
des a 490-amino-acid protein that shows 38% identity with
the human C21orf80b protein.
Fig. 1. (A) Schematic representation of the three C21orf80 mRNA isoforms identified. Exons are represented as numbered boxes, introns are shown as thin
lines, start and stop codons are indicated. Two different mRNA species of 3.0 and 2.3 kb were detected. Northern blot analysis was performed using a probe
designed to detect all three C21orf80 mRNA isoforms. (B) Multiple sequence alignment of the deduced amino acid sequence of the human C21orf80b
(AJ302079), the mouse C21orf80 ortholog (AF455270), the C. elegans C21orf80 ortholog (AF455271), and the Drosophila ortholog O-fucosyltransferase 2
CG14789-PA (AAF45629). The mouse C21orf80 cDNA was isolated by assembling ESTs (BG915839, BI646651, AI550762). Identical amino acids are
shaded in black. Conserved amino acids are shaded in gray.
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Expression pattern and intracellular localization of
C21orf80
Northern blot analysis revealed a ubiquitous band of
approximately 3 kb that could correspond to C21orf80b
and/or c. A faint 2.5-kb band was also observed in brain
(Fig. 1A). RT-PCR was performed on a panel consisting of
24 human cDNA samples [28] to determine the expression
profile of each of the three C21orf80 transcripts. C21orf80a
was found to be expressed in fetal liver and peripheral blood
lymphocytes. C21orf80b was detected in spleen, lung, testis,
bone marrow, fetal brain, fetal liver, fetal kidney, thymus,
pancreas, and prostate. C21orf80c was detected in brain,
heart, spleen, liver, lung, stomach, testis, placenta, skin, fetal
brain, fetal liver, fetal heart, thymus, pancreas, mammary
gland, and prostate (data not shown).
To determine where C21orf80 might exert its cellular
function, EGFP–C21orf80 or HA–C21orf80 proteins were
expressed in COS-7 and U2OS cells. In both cell types,
C21orf80 proteins were found in the cytoplasm chiefly in
one or more perinuclear spots (Fig. 2). To define better the
compartments identified by C21orf80 proteins, colocaliza-
tion experiments were performed in COS-7 cells using
markers specific for the Golgi apparatus, the endoplasmic
reticulum, and the microtubule network. The results showed
that C21orf80 proteins colocalize to some extent with
Giantin, a Golgi apparatus-specific protein (Fig. 2, data
not shown for C21orf80a and c).
pad-2(RNAi) embryos show patterning defects
We used RNA-mediated interference (RNAi) to investi-
gate the role of pad-2, theC. elegans ortholog ofC21orf80, in
development. pad-2, previously described as a predicted gene
(K10G9.3), had not been considered a genuine ORF and
thereby avoided large-scale RNAi screening. Feeding worms
with bacteria expressing pad-2 double-stranded RNA
(dsRNA) caused embryonic lethality at an average pene-
trance of 17% (Table 1). The affected pad-2(RNAi) embryos
arrested growth and development at various stages, beginning
at the onset of morphogenesis, when terminal differentiation
occurs [15,30]. They also displayed obvious body malforma-
tions owing to the failure in embryonic patterning and
elongation (Figs. 3B, 3D, 3G, and 3K). The presence of
autofluorescent gut granules (Fig. 3B) as well as the expres-
sion of the epidermal marker jam-1Dgfp (Fig. 3H), the
neuron-specific unc119Dgfp (Fig. 3L), and the body wall
muscle reporter myo-3Dgfp (data not shown) suggested that
at least some cell types were properly differentiated in pad-
2(RNAi) embryos [6,18,22]. However, the gut granules were
mislocalized at the periphery of the arrested embryos (Figs.
3A and 3B), the epidermal cells were tightly clustered and
displayed abnormal size and shape (Figs. 3F and 3H), and the
prospective ventral nerve cord was either absent or mislo-
calized in 10% of the pad-2(RNAi) embryos (Figs. 3J and 3L).
The body wall muscle marker myo-3Dgfp also indicated,
although with a moderate penetrance, cell patterning defects.
These data demonstrate that pad-2 is required for embryonic
morphogenesis by controlling body elongation and position-
ing of several cell types, including intestinal, hypodermal,
body wall muscle, and neuronal cells.
Inactivation of pad-2 by RNAi disrupts cellular integrity and
decreases fertility
pad-2 dsRNA treatment caused a highly variable and
incomplete penetrant phenotype during postembryonic de-
velopment. Approximately f2% of pad-2(RNAi) animals
arrested development at different larval stages or at young
adulthood, exhibiting severe body malformations (data not
shown). The viable pad-2(RNAi) larvae and adults were
characterized by loss or significant reduction of UNC-
119DGFP staining in the ventral nerve cord neurons (Fig.
4B) and in other neuronal cells (not shown). Upon differ-
ential interference contrast microscopy, the majority of
these neurons did not show signs of degeneration during
development but rather an irregular size and position. The
integrity of the axonal bundles also appeared to be dis-
rupted. Furthermore, using the myo-3Dgfp marker high-
lighting myosin heavy chain A, structural changes in the
body wall muscle cells of pad-2(RNAi) worms were ob-
served. In wild-type animals, the muscle cell sarcomeres
were organized in tight parallel symmetric rows (Fig. 4C).
In pad-2(RNAi) worms the sarcomeres became disorganized
with marked signs of irregular orientation (Fig. 4D).
Changes in neuronal or muscle cell structure, or both, can
explain the egg-laying-defective (Egl) phenotype (<5%)
observed in pad-2(RNAi) hermaphrodites (not shown).
Occasionally, pad-2(RNAi) hermaphrodites displayed obvi-
ous defects in vulval development owing to abnormal
orientation of vulval cell division (data not shown), which
might have contributed to the observed Egl and/or everted
vulva phenotypes.
The fertility of pad-2(RNAi) hermaphrodites was highly
reduced. We found a mean ‘‘brood size’’ (all laid eggs) of
96F 16.5 in pad-2(RNAi) adults versus 191 F 14.5 in wild-
type animals. A portion of the oocytes produced by the
RNAi-treated animals remained unfertilized after passing
through the spermatheca (Fig. 4F). Although the spermato-
zoids looked normal, their number was significantly lower
in 7 of 10 pad-2(RNAi) hermaphrodites (85–135 sperma-
tozoids/spermatheca in pad-2(RNAi) hermaphrodites in con-
trast to 170–195 in wild-type animals, n = 10). A similar
phenomenon was observed in pad-2(RNAi) males (data not
shown), indicating that pad-2 affects spermatozoid differ-
entiation in both sexes.
Overexpression of pad-2 affects morphogenesis
In an effort to dissect the potential implication of three
copies of C21orf80 in DS, we have evaluated the effect of
an increased dose of pad-2 on C. elegans development.
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Fig. 2. Intracellular localization of the C21orf80 protein. Fluorescence microscopic analysis of fixed COS-7 or U2OS cells transiently transfected with (A)
EGFP-C21orf80 (COS-7 cells, green signal), (B) HA-TMPRSS3 (COS-7 cells, red signal), (C) EGFP-C21orf80 (U2OS cells, green signal), and (D) HA-
C21orf80 (U2OS cells, red signal) and counterstained with 4V,6-diamidine-2V-phenylindole dihydrochloride (A, B, C, and D, blue signal). Fixed COS-7 cells
transiently transfected with (E) EGFP-C21orf80 (green signal) and (F) counterstained with Golgi apparatus marker (anti-Giantin antibody, red signal). (G)
Colocalization of EGFP-C21orf80 with Golgi marker.
Overexpression of pad-2 from a heat-inducible promoter cells are sensitive to excessive and/or ectopic pad-2 dosage.
that is active in almost all somatic cells [5] caused a highly The developmental stage at which the affected embryos
penetrant embryonic lethality (83%, Table 2) accompanied arrested growth varied highly among individuals. To restrict
by severe body malformations, indicating that embryonic the overexpression of pad-2 to the appropriate tissues and to
Fig. 3. Depletion of pad-2 by RNAi causes defects in embryonic patterning. (A) Differential interference contrast (DIC) image of a comma stage (390 min)
wild-type embryo and (B) a 390-min pad-2(RNAi) embryo that failed to undergo elongation. Arrows point to the autofluorescent gut granules that are located
abnormally to the periphery in the pad-2(RNAi) embryo. (C) DIC image of a wild-type and (D) a pad-2(RNAi) 2-fold-stage embryo. (E) DIC image and (F)
corresponding fluorescence micrograph of a 350-min wild-type embryo transgenic for the epidermal adherent junction marker jam-1Dgfp. (G) DIC and (H)
fluorescence images of a 380-min pad-2(RNAi) embryo. The hypodermal (green) and intestinal (yellowish) cells are tightly clustered. (I) DIC image and (J)
corresponding fluorescence micrograph of a 1.5-fold-stage (400-min) wild-type embryo bearing the neuronal marker unc-119Dgfp. (K) DIC and (L)
fluorescence images of a 400-min pad-2(RNAi) embryo transgenic for unc-119Dgfp. Mislocalization of the prospective ventral nerve cord (indicated by an
arrowhead in J in the wild type) is evident. The RNAi-treated embryos shown in B, D, G/H, and K/L arrested growth and development at different stages. Bars
represent 20 Am.
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Table 1
Lethality of pad-2(RNAi) embryos
Bacterial strain used for feeding No. of % of % of
embryos dead viable
examined embryos embryos
HT115(DH3) (control) 1410 6.6 93.4
HT115(DH3) pad-2 dsRNA 2119 23.9 76.1
levels observed in trisomy 21, we injected the cosmid
K10G9, which contains the pad-2 coding region and 3 kb
of upstream regulatory sequences, into wild-type animals.
Consistent with the heat-shock data, animals transgenic for
K10G9 showed a moderate percentage of embryonic lethal-
ity (5.1%, Table 2) and early larval arrest characterized by
mild to severe morphogenetic abnormalities (Figs. 5A, 5B,
5D, and 5E). Although the K10G9-transgenic arrested
animals exhibited almost normal body elongation and tissue
differentiation, they showed obvious patterning defects that
were manifested in severe body malformations mainly in
the head and tail as well as in protrusions along the entire
anteroposterior body axis.
Levels of transgene expression were estimated by
semiquantitative PCR that showed increased dose of pad-
2 mRNA in both transgenic strains (hsDpad-2 and cosmid
K10G9) compared to wild-type animals (Fig. 5F). It must
be noted that we could not formally exclude the possible
effect of K10G9.2, the only other full-length gene present
in cosmid K10G9, on the observed phenotype. However,
overexpressing pad-2 under a heat shock promoter or its
own promoter resulted in the same phenotype character-
ized by embryonic lethality associated with various mor-
phological defects. Furthermore, consistent with the level
of pad-2 overexpression, the penetrance of this phenotype
was much higher when pad-2 was overexpressed under a
heat shock promoter. Taken together, our experimental
results indicate that embryonic lethality in animals trans-
genic for cosmid K10G9 was caused by extra copies of
pad-2.
To evaluate the effects of elevated pad-2 dose on cell
fate determination, we examined the expression of the
neuronal marker unc-119Dgfp in animals transgenic for
K10G9. Interestingly, we detected a more intense and
ectopic UNC-119DGFP accumulation in the K10G9 trans-
genic embryos compared with the wild-type expression
pattern (Figs. 5G–5N). For example, the border of the
UNC-119DGFP-positive area in the head was slightly
shifted toward the posterior pole. Furthermore, certain
neurons, for example those that belong to the ventral nerve
cord, expressed UNC-119DGFP at abnormally high levels.
This observation is consistent with the characterization of
the pad-2 RNAi phenotype, which revealed a faint and
reduced UNC-119DGFP expression relative to that found
in the wild type. These data suggest that pad-2 influences
cell identity at least in neurons in a dosage dependent
manner.
pad-2 is expressed in different cell types from
morphogenetic embryonic stages throughout development
The expression pattern of pad-2 was analyzed by using
animals carrying a pad-2Dgfp reporter, swEx571, tagged
with a nuclear localization signal. Consistent with the
observed pad-2 RNAi phenotypes, pad-2 expression starts
during the morphogenetic period of embryonic develop-
ment. At this stage it was detectable in the anterior part of
the embryos, in the hypodermal and neuronal cells of the
head (Fig. 6A). After the animal hatched, pad-2 was
expressed at different levels in a variety of cell types,
including neuronal, hypodermal, muscle, intestinal, and
somatic gonadal cells (Fig. 6C and data not shown). PAD-
2DGFP accumulation was most intense in the nerve ring
around the pharynx (Fig. 7A), in the dorsal and ventral
nerve cords (Fig. 7B), in the intestine, and in a variety of
hypodermal cells (Fig. 7C) of the L1–L3-stage larvae. In
Fig. 4. pad-2 RNAi affects the integrity of neuronal and body wall muscle cells and reduces fertility. (A) Ventral nerve cord (arrow) in a wild-type L4-stage
larva expressing the neuronal marker UNC-119DGFP. (B) Many of the ventral cord neurons failed to express UNC-119DGFP in a pad-2(RNAi) L4 larva. The
integrity of the axonal bundles is also disrupted (arrow). (C and D) Fluorescence micrographs showing a body wall muscle cell from a wild-type and a pad-
2(RNAi) L4 larva, respectively. Both animals are transgenic for the body wall muscle marker myo-3Dgfp. Sarcomeres are organized in tight symmetric parallel
rows in the wild-type animal, whereas they reflect irregular orientation in the pad-2 RNAi-treated animal. (E and F) DIC images of wild-type and pad-2(RNAi)
hermaphrodites, respectively. The white-filled arrow shows the vulva, the black arrow points to the spermatheca. As the oocytes pass through the spermatheca,
they start to divide in the wild-type animals but remain unfertilized in the pad-2(RNAi) animals. Bars represent 20 Am in A, B, E, and F and 10 Am in C and D.
Fig. 5. Elevated dosage of pad-2 causes defects in morphogenesis and influences the expression of the neuronal marker UNC-119DGFP. (A) Wild-type 420-
min-stage embryo. (B) Arrested 420-min-stage embryo transgenic for the cosmid K10G9 shows severe morphogenetic defects. (C) Wild-type L1 larva. (D, E)
L1 larvae transgenic for K10G9 display mild or severe body malformations. (F) Semiquantitative RT-PCRs were performed to determine the levels of pad-2
mRNA in (lane 1) wild-type animals and (lane 2) hsDpad-2 and (lane 3) K10G9 transgenic animals. The ubiquitously expressed ama-1 mRNA (426 bp) was
used as an internal control. Strains transgenic for hsDpad-2 and K10G9 show an elevated level of pad-2 mRNA relative to wild-type animals (lane 1). (G, H)
DIC and fluorescence images of a gastrula transgenic for unc-119Dgfp. (I, J) Embryo at the same stage as in G and H is transgenic for both K10G9 and unc-
119Dgfp. (K, L) Comma-stage embryo transgenic for unc-119Dgfp. (M, N) Comma-stage embryo transgenic for both K10G9 and unc-119Dgfp. The presence
of K10G9 causes ectopic and more intense UNC-119DGFP expression relative to that found in the wild type. (G, I, K, M) DIC images and (H, J, L, N)
corresponding fluorescence images. The epifluorescence images were captured with the same exposure time. Anterior is left, dorsal up. Bars represent 20 Am.
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Fig. 4.
Fig. 5.
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Table 2
Overexpression of pad-2 results in embryonic arrest
Strains No. of eggs % of embryonic
examined lethality
N2a without heat shock Many 0.5
N2 with heat shock 713 10.1
FR710b without heat shock 956 3.2
FR710 with heat shock 1228 86
FR711c 742 5.1
a Wild-type strain.
b Strain transgenic for the hs::pad-2/rol-6 array.
Strain transgenic for the cosmid K10G9.
adult hermaphrodites, gonadal sheath cells, spermatheca,
and tissues surrounding the vulva showed intense pad-2
expression (Fig. 7D). These observations are consistent with
sterility and vulva-specific phenotypes found in pad-
2(RNAi) hermaphrodites. PAD-2DGFP was also expressed
in the body wall muscle and hypodermal cells in both sexes
(Figs. 7F and 7G).
Discussion
Down syndrome is a complex disorder caused by
trisomy of Hsa21. The current hypothesis for how trisomy
21 leads to DS is that some genes, but not all, contribute
to aspects of the DS phenotype. Clarifying the roles of
individual Hsa21 genes in DS requires both overexpres-
sion and knockout approaches in model organisms. Here,
we describe the isolation and initial characterization of
C21orf80, a potential new protein O-fucosyltransferase.
C21orf80 is ubiquitously expressed in human tissues and
may primarily localize in the Golgi apparatus, two char-
acteristics of many other glycosyltransferases [14]. High
level of homology among human, mouse, Drosophila, and
C. elegans C21orf80 proteins indicates an evolutionarily
conserved biological role. Recent studies have provided
evidence of a role for O-fucosylation in signal pathways
involved in development [11]. The most remarkable ex-
ample is the demonstration that O-fucose modification by
protein O-fucosyltransferase (OFUT1) is essential for
most, and possibly all, aspects of Notch signaling
[24,25]. Based on these results, we hypothesize that
overexpression of C21orf80 in DS could lead to variation
in the profile of O-fucosylation on target proteins, influ-
encing their function by eliciting a new conformational
change or masking or creating new recognition sites
between proteins.
To investigate the biological role of C21orf80 and its
potential involvement in DS, we isolated its C. elegans
ortholog, pad-2. Downregulation of pad-2 resulted in a
pleiotropic phenotype observed at different stages of
development. Consistent with the onset of pad-2 expres-
sion during the morphogenetic period of embryonic de-
velopment, affected pad-2(RNAi) embryos failed to
undergo normal morphogenesis and showed arrested de-
velopment. A more detailed analysis of the embryonic
phenotype revealed abnormal positioning of several cell
types without apparently affecting tissue differentiation.
For example, the prospective ventral nerve cord, the
intestine, the hypodermis, and the body wall muscle cells
were mislocalized or partially formed in a fraction of pad-
2(RNAi) embryos.
Most of the tissues expressing pad-2 at the larval and
adult stages were affected upon RNAi, although the pene-
trance of postembryonic phenotypes was highly incomplete.
pad-2(RNAi) adult hermaphrodites displayed abnormal vul-
val development and reduced fertility, consistent with strong
pad-2 expression in developing vulval tissue of L3 and L4
stage larvae and in the gonadal sheath cells and spermatheca
of adult hermaphrodites. These observations suggest that
pad-2 is involved in vulval cell fate specification as well as
germ cell generation. pad-2(RNAi) larvae also showed
obvious cell fate specification defects in certain neurons,
especially in the ventral nerve cord, consistent with strong
expression of pad-2 in these cells. This suggests a role for
pad-2 in neuronal development and survival. pad-2 is also
required for the integrity of body wall muscle cells by
controlling the orientation of sarcomeres. Even observed
at incomplete penetrance, these phenotypes were considered
significant as they were reproducible and never observed in
wild-type animals.
Overexpression of pad-2 under the control of a heat
shock promoter that is active in most somatic cells
resulted in highly penetrant embryonic lethality, indicating
that the correct dose of pad-2 is critical for normal
development. However, strong overexpression of many
genes in a nonphysiological manner will almost certainly
result in an apparent phenotype [19,32]. Therefore, trans-
genic worms were generated with the cosmid K10G9,
which contains pad-2 and its endogenous regulatory sequen-
ces. K10G9 transgenic animals also showed embryonic
lethality and morphogenetic defects. Our findings suggest
that a correct dosage of pad-2 is necessary for normal
development.
C. elegans neuronal development was affected in both
pad-2(RNAi) and K10G9 transgenic embryos. Notably, pad-
2 downregulation or overexpression caused disorganization
of the developing neuronal network in the opposite manner.
Absence of pad-2 resulted mostly in the loss or reduced
expression of a neuronal marker, whereas pad-2 overex-
pression seemed to activate neuronal proliferation and/or
specification. This implies that pad-2 may act as a coordi-
nator of cell fate specification and tissue patterning during
embryonic neural development.
Interestingly, the gene defective in leukocyte adhesion
deficiency II (LADII) encodes a putative GDP-fucose
transporter [16,17]. The fucosylation of glycoproteins
was found to be defective in individuals with LADII
who suffer from severe infections, persistent leukocytosis,
short stature, unusual facial and skeletal abnormalities,
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Fig. 6. Early expression of pad-2 during C. elegans development. pad-2 is
expressed ubiquitously from the onset of embryonic morphogenesis
throughout development. (A) Fluorescence micrograph of a 2-fold-stage
embryo expressing PAD-2DGFP. PAD-2DGFP fluorescence is detectable
in the anterior part of the body. (C) L1 larva showing PAD-2DGFP
accumulation in different cell types, including hypodermal, intestinal,
neuronal, and muscle cells. (B, D) Corresponding DIC images of the same
animals. The yellowish color in A indicates gut autofluorescence. White
arrows in B and D point to the head. Bars represent 20 Am.
and severe mental retardation pointing to the importance
of fucosylation for the development of the neuronal
system.
Taken together, these results suggest a potential role for
C21orf80 in DS phenotypes.
Materials and methods
Isolation of the human C21orf80 cDNA and gene
Detailed analysis of 21q22.3 genomic DNA (GenBank
Nos. AL163300, AL163301, and AL163302) was per-
formed using numerous computer programs, interfaced by
NIX (http://www.hgmp.mrc.ac.uk/NIX/), a program that
integrates most of the gene identification programs. Subse-
quently, 5V- and 3V-RACE and RT-PCR reactions were
performed on human brain, placenta, and liver cDNAs using
primers designed within predicted exons of a novel gene
named C21orf80. The sequence of the primers used is
available at http://www.medgen.unige.ch. The genomic
structure and intron–exon junctions of C21orf80 were
determined by comparison of the genomic sequence with
the cDNA sequences by using est_genome software (http://
www.hgmp.mrc.ac.uk). C21orf80 protein sequences were
analyzed using the Tools and software packages at the
Expasy Molecular Biology Server (http://au.expasy.org/).
Expression pattern of C21orf80
Northern blot analysis was performed on a commercially
available blot (Origene Technologies, Rockville, MD, USA)
containing 2 Ag of poly(A)+ RNA from six adult tissues
according to the manufacturer’s recommendations. A partial
cDNA clone spanning exons 4 to 9 of the C21orf80b
transcript was used as a probe. The absence of C21orf80
transcript in spleen is likely to be due to the very low
quantity of spleen mRNA blotted on the membrane as
Fig. 7. Expression of pad-2 in larval and adult stages. (A, B, C) Fluorescence micrographs showing PAD-2DGFP accumulation in the anterior, middle, and
posterior body part of L2 larvae, respectively. (A) In the head, PAD-2DGFP is detectable in the nerve ring (arrow) and in the anterior hypodermal cells, hyp 3–
6 (arrowheads). (B) In the midbody region, neurons that belong to the dorsal and ventral nerve cords indicated as dc and vc express pad-2. (C) PAD-2DGFP
also accumulates in all intestinal (i) and many hypodermal cells (hyp 11). (D) Expression of pad-2 in a young adult hermaphrodite. Vulval cells show intense
PAD-2DGFP accumulation. Arrows point to the spermatheca where pad-2 is also active. (E) Enlarged nucleus of a pad-2Dgfp-expressing cell showing the
presence of discrete foci of fluorescence that appear over the more diffuse background fluorescence. (F) pad-2 is intensely expressed in the body wall muscle
sarcomeres. (G) PAD-2DGFP accumulation in the posterior body part of an adult male shows pad-2 expression in hypodermal, muscle, and neuronal cells. The
bracket indicates the tail (rays). Bars represent 40 Am.
O. Menzel et al. / Genomics 84 (2004) 320–330
shown by the weak signal obtained with the h-actin control
probe. RT-PCR was performed on a panel consisting of 24
human cDNA samples prepared as described [28]. The
sequences of the primers used in this analysis are available
on our Web page: http://www.medgen.unige.ch/.
Intracellular localization of C21orf80 proteins
To visualize the intracellular localization of the C21orf80
proteins, COS-7 and U2OS cells were transiently transfected
with vectors expressing either 5VEGFP- or 5VHA-tagged
C21orf80 proteins as previously described [29]. To perform
colocalization with known subcellular compartments, trans-
fected COS-7 and U2OS cells were incubated with antibodies
recognizing specific cellular structures: Golgi by a mouse anti-
Giantin antibody (Calbiochem, San Diego, CA, USA); anti-a,
-h, and -y tubulin antibodies (Sigma–Aldrich, Munich, Ger-
many), and the dye Endoplasmic Reticulum-Tracker Blue-
White DPX (Molecular Probes, Eugene, OR, USA).
Isolation of pad-2 cDNA, the C. elegans ortholog of
C21orf80
The C. elegans ortholog of the human C21orf80 gene
was identified by tBLASTn using the human protein se-
quence against the C. elegans genomic DNA sequence. The
full-length coding sequence of pad-2 was isolated by RT-
PCR using C. elegans poly(A)+ RNA. The genomic struc-
ture and intron–exon junctions of pad-2 were determined
by comparison of the genomic sequence with the cDNA
sequence by using est_genome software (http://
www.hgmp.mrc.ac.uk). The sequence of the primers used
is available at http://www.medgen.unige.ch.
C. elegans strains, alleles, and general methods
C. elegans strains were maintained using standardmethods
[1]. Wild-type worms correspond to C. elegans var. Bristol,
strain N2. Other strains were FR709 swEx573[hsDpad-2 +
rol-6(su1006)]; FR710 swEx574[hsDpad-2 + rol-6(su1006)];
DP132 edIs[unc-119Dgfp + rol-6(su1006)]IV; FR711
swEx575[K10G9 + rol-6(su1006)]; FR706 swEx571[pad-
2Dgfp + ro-6(su1006)]; FR707 swEx572[pad-2Dgfp + ro-
6(su1006)]; FR775 CcIs4251[myo-3Dgfp + dpy-20(+)]V,
dpy-20(e1362)IV; su93 jcIs1[jam-1Dgfp + rol-6(su1006) +
unc-29(+)]IV [22]; and DP132 edIs[unc-119Dgfp +
rol-6(su1006)]IV [18]. The unc-119Dgfp, myo-3Dgfp and
jam-1Dgfp reporters were used as neuronal, muscle, and
epidermal markers, respectively. The strain expressing the
hsDpad-2/rol-6 array was maintained at 15jC, other strains
were analyzed at 22jC.
RNAi assay
A 951-bp fragment of the pad-2 cDNAwas amplified by
RT-PCR u s i n g p r im e r s 5 V-CCGCTCGAGCG-
GACCGTGTCTCGGGTGGACTCGAAC-3V and 5V-
[GGACTAGTCCAACAGAGCTTTGAGCTCATCGAC-3V
and subcloned into pPD129.36 [6]. This construct, called
pGEN1, was transformed into HT115(DE3) Escherichia
coli strain. Bacteria containing pGEN1 were grown and
induced as described [13], then seeded directly onto nem-
atode growing medium (NGM) plates with 1 mM IPTG and
50 Ag/ml ampicillin. To examine the effects of pad-2 RNAi,
wild-type L4-stage larvae were transferred onto NGM plates
seeded with bacteria that were expressing pad-2 dsRNA,
and the F1 siblings were analyzed.
Overexpression of pad-2
The pad-2 cDNA was digested with restriction enzymes
NheI/KpnI and cloned into pPD49.83, which contains the C.
elegans hsp16-41 heat-inducible promoter [4]. This con-
struct, called pGEN2 (hsDpad-2), was co-injected with
pRF4 carrying the dominant transformation marker gene
rol-6(su600) at 50 ng/Al concentration into young adult
hermaphrodites as previously described [21]. Worm lines
transgenic for the hsDpad-2/rol-6 array were established
(strains FR709 and FR710) and heat shocked three or four
times, each round being 33jC for 30 min followed by 20jC
for 3 h and 30 min. The cosmid K10G9, which contains
pad-2(K10G9.3) and its upstream regulatory sequences
(http://www.wormbase.org), was also injected into young
hermaphrodites, and a transgenic line (strain FR711) was
established. To examine neuronal development in K10G9
transgenic animals, the strains FR711 and DP132 (unc-
119Dgfp) were crossed.
Analysis of pad-2 overexpression was performed by RT-
PCR. Total RNAwas isolated from 30 wild-type, hsDpad-2
transgenic, or K10G9 transgenic L4-stage larvae. pad-2 and
ama-1 mRNAs were amplified by the Qiagen one-step RT-
PCR system using primers 5V-AAATTCGAGAAACG-
GAGCTG-3V and 5V-TACTCCTTCTCGCCTTCCAG-3V
for pad-2, 5V-CAGTGGCTCATGTTCGAGT-3V and 5V-
CGACCTTCTTTCCATCAT-3V for ama-1. PCR products
were separated on agarose gel and transgene expression
levels were estimated using the respective intensity of the
ethidium bromide bands using the Multi-Analyst software
(Bio-Rad).
Expression analysis of pad-2
A 5-kb genomic fragment containing the first three exons
of pad-2 and 3 kb of upstream sequence (the closest
upstream gene, R01H10.8, is located 2 kb from pad-2)
was cloned into pPD95.69 (provided by A. Fire). This
construct, called pGEN3, expresses the PAD-2DGFP fusion
protein tagged with a nuclear localization signal under the
control of the pad-2 endogenous promoter. pGEN3 was co-
injected with pRF4 into wild-type hermaphrodites. Two
transgenic lines (FR706 and FR707) were established and
examined using a Leica DM RXA epifluorescence micro-
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scope equipped with DIC optics. Images were taken with a
Hamamatsu chilled CCD camera (C5985) and processed
with the Argus-20 Image Processor (Hamamatsu) using
Adobe PhotoShop (4.0).
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